Literature DB >> 33502736

Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease.

Fatemeh Rezaei Rad1, Masood Ghahvechi Akbari2, Majid Zamani3, Shiva Bayat1, Mahdi Zamani4.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting cognitive function. A number of allelic genes from HLA complex have shown variable associations with AD in different populations. In this study, we investigated the association of DQB1*06:00/x, DRB1*04:00/x, DRB1*15:00/x, and B*07:00/x genotypes with AD and their relevance to the efficacy of rivastigmine treatment in the Iranian population. Our findings suggest that DQB1*06:00/x genotype offers strong protection against AD (P = 0.0074), while B*07:00/x genotype imposes a significant susceptibility for sporadic Alzheimer's disease (SAD) (P = 0.009). Interestingly, B*07:00/x genotype does not show any apparent associations with familial Alzheimer's disease (FAD). Our studies also suggest a pharmacogenetic relationship between drug treatment and presence of a particular genotype in the Iranian LOAD patient population. The Clinical Dementia Rating analysis showed that LOAD patients carrying DRB1*04:00/x genotype tend to display a downward trend in the disease severity and symptoms after 2-year follow-up with rivastigmine treatment. Moreover, in our total patient population, the carriers of DQB1*06:00/x and B*07:00/x alleles have better and worse responses to rivastigmine respectively. We also measured the clinical relevance of the testing for these genotypes employing prevalence-corrected positive predictive value (PcPPV) formula. The PcPPV of testing for DQB1*06:00/x in the Iranian LOAD patients was 1.17% which means that people carrying this genotype have half of the probability of the absolute risk for developing LOAD, whereas the PcPPV of testing for B*07:00/x was 4.45% for SAD, which can be interpreted as a doubling chance for developing LOAD among the Iranian population carrying this genotype. These results also suggest that DQβ1 peptide containing positively charged AAs histidine30 and arginine55 and HLA class I β chain containing negatively charges aspartic acid114 and glutamic acid45,152 in their binding groove plays important roles in protection against and susceptibility for LOAD respectively.

Entities:  

Keywords:  Alzheimer; HLA genes; PCR; Pharmacogenetic; Rivastigmine

Year:  2021        PMID: 33502736     DOI: 10.1007/s12035-021-02295-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  38 in total

Review 1.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses.

Authors:  Lars Bertram; Rudolph E Tanzi
Journal:  Nat Rev Neurosci       Date:  2008-10       Impact factor: 34.870

2.  Effects of HLA-DRB1/DQB1 Genetic Variants on Neuroimaging in Healthy, Mild Cognitive Impairment, and Alzheimer's Disease Cohorts.

Authors:  Zi-Xuan Wang; Hui-Fu Wang; Lin Tan; Jinyuan Liu; Yu Wan; Fu-Rong Sun; Meng-Shan Tan; Chen-Chen Tan; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2016-04-07       Impact factor: 5.590

3.  Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group.

Authors:  W A Rocca; A Hofman; C Brayne; M M Breteler; M Clarke; J R Copeland; J F Dartigues; K Engedal; O Hagnell; T J Heeren
Journal:  Ann Neurol       Date:  1991-09       Impact factor: 10.422

Review 4.  Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal.

Authors:  Giuseppina Candore; Carmela Rita Balistreri; Giuseppina Colonna-Romano; Domenico Lio; Calogero Caruso
Journal:  Exp Gerontol       Date:  2004-04       Impact factor: 4.032

5.  ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia.

Authors:  J Chapman; N Wang; T A Treves; A D Korczyn; N M Bornstein
Journal:  Stroke       Date:  1998-07       Impact factor: 7.914

Review 6.  APP processing in Alzheimer's disease.

Authors:  Yun-wu Zhang; Robert Thompson; Han Zhang; Huaxi Xu
Journal:  Mol Brain       Date:  2011-01-07       Impact factor: 4.041

7.  Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients.

Authors:  M Zamani; M Mehri; A Kollaee; P Yenki; M Ghaffarpor; M H Harirchian; M Shahbazi
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-06-29

8.  Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study.

Authors:  Natasha Z R Steele; Jessie S Carr; Luke W Bonham; Ethan G Geier; Vincent Damotte; Zachary A Miller; Rahul S Desikan; Kevin L Boehme; Shubhabrata Mukherjee; Paul K Crane; John S K Kauwe; Joel H Kramer; Bruce L Miller; Giovanni Coppola; Jill A Hollenbach; Yadong Huang; Jennifer S Yokoyama
Journal:  PLoS Med       Date:  2017-03-28       Impact factor: 11.069

9.  Late-onset Alzheimer disease risk variants mark brain regulatory loci.

Authors:  Mariet Allen; Michaela Kachadoorian; Minerva M Carrasquillo; Aditya Karhade; Lester Manly; Jeremy D Burgess; Chen Wang; Daniel Serie; Xue Wang; Joanna Siuda; Fanggeng Zou; High Seng Chai; Curtis Younkin; Julia Crook; Christopher Medway; Thuy Nguyen; Li Ma; Kimberly Malphrus; Sarah Lincoln; Ronald C Petersen; Neill R Graff-Radford; Yan W Asmann; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner
Journal:  Neurol Genet       Date:  2015-07-23

10.  The worldwide costs of dementia 2015 and comparisons with 2010.

Authors:  Anders Wimo; Maëlenn Guerchet; Gemma-Claire Ali; Yu-Tzu Wu; A Matthew Prina; Bengt Winblad; Linus Jönsson; Zhaorui Liu; Martin Prince
Journal:  Alzheimers Dement       Date:  2016-08-29       Impact factor: 21.566

View more
  1 in total

1.  Empirical Study of Large-Scale HLA Simulation of Parallel Region-Matching Knowledge Recognition Algorithm Based on Region Matching.

Authors:  Guohua Zhu; Haizhou Wang
Journal:  Comput Intell Neurosci       Date:  2022-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.